ArticleCancer medicine2017

Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractory multiple myeloma patients.

Rouslan Kotchetkov et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.